{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:30:12Z","timestamp":1787729412332,"version":"build-2784847793"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health, USA","doi-asserted-by":"crossref","award":["ZIA DA000424"],"award-info":[{"award-number":["ZIA DA000424"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.neuropharm.2017.09.007","type":"journal-article","created":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T03:33:52Z","timestamp":1504755232000},"page":"190-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["The novel dopamine D3 receptor antagonists\/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats"],"prefix":"10.1016","volume":"126","author":[{"given":"Zhi-Bing","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Tao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hua","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Comfort","family":"Boateng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot L.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Hauck","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6482-8104","authenticated-orcid":false,"given":"Zheng-Xiong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.09.007_bib1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/jpet.115.224121","article-title":"Dopamine D3 receptor antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs","volume":"354","author":"Appel","year":"2015","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrn3104","article-title":"Opiate versus psychostimulant addiction: the differences do matter","volume":"12","author":"Badiani","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib3","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1021\/acs.jmedchem.5b00776","article-title":"High affinity dopamine D3Receptor (D3R)-Selective antagonists attenuate heroin self-administration in wild-type but not D3R knockout mice","volume":"58","author":"Boateng","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib4","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1523\/JNEUROSCI.4371-11.2012","article-title":"Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study","volume":"32","author":"Boileau","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib5","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1126\/science.8099761","article-title":"Modulation of cocaine self-administration in the rat through D-3 dopamine receptors","volume":"260","author":"Caine","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2015.04.071","article-title":"Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: a national study","volume":"167","author":"Cerd\u00e1","year":"2015","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/npp.2015.272","article-title":"Translational studies of sex differences in sensitivity to opioid addiction","volume":"41","author":"Chartoff","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2016.8897","article-title":"Improving outcomes for persons with opioid use disorders: Buprenorphine implants to improve adherence and access to care","volume":"316","author":"Compton","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib9","doi-asserted-by":"crossref","first-page":"E5511","DOI":"10.1073\/pnas.1605295113","article-title":"A\u00a0novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates","volume":"113","author":"Ding","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.appet.2012.03.007","article-title":"Effect of the dopamine D3 receptor antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters","volume":"59","author":"Dodds","year":"2012","journal-title":"Appetite"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib11","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib12","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-004-1807-9","article-title":"Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference","volume":"175","author":"Franc\u00e8s","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib13","first-page":"264","article-title":"In\u00a0vivo analysis of the role of dopamine in stimulant and opiate self-administration","volume":"21","author":"Gratton","year":"1996","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1749-6632.2009.05149.x","article-title":"Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders","volume":"1187","author":"Heidbreder","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib15","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1021\/jm501512b","article-title":"Identifying medication targets for psychostimulant addiction: unraveling the dopamine D3 receptor hypothesis","volume":"58","author":"Keck","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib16","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1021\/acs.jmedchem.6b00860","article-title":"Highly selective dopamine D3Receptor (D3R) antagonists and partial agonists based on eticlopride and the D3R crystal structure: new leads for opioid dependence treatment","volume":"59","author":"Kumar","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/syn.10170","article-title":"Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats","volume":"47","author":"Le Foll","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.pbb.2005.08.008","article-title":"Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats","volume":"82","author":"Leri","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00000542-200702000-00020","article-title":"Opioid self-administration in the nerve-injured rat","volume":"106","author":"Martin","year":"2007","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib21","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib52","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00213-017-4536-6","article-title":"Oxycodone self-administration in male and female rats","volume":"234","author":"Mavrikaki","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/pop.2013.0098","article-title":"Prescription opioid abuse: a literature review of the clinical and economic burden in the United States","volume":"17","author":"Meyer","year":"2014","journal-title":"Popul. Health Manag."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/13543776.2013.757593","article-title":"Dopamine D3 receptor antagonists: a patent review (2007-2012)","volume":"23","author":"Micheli","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/npp.2012.171","article-title":"Occupancy of brain dopamine D3 receptors and drug craving: a translational approach","volume":"38","author":"Mugnaini","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib25","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/npp.2016.289","article-title":"Acute D3 antagonist GSK598809 selectively enhances neural response during monetary reward anticipation in drug and alcohol dependence","volume":"42","author":"Murphy","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib26","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.npp.1300456","article-title":"Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior","volume":"29","author":"Neisewander","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib27","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1021\/jm040190e","article-title":"Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents","volume":"48","author":"Newman","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/dar.12418","article-title":"Opioid agonist doses for oxycodone and morphine dependence: findings from a retrospective case series","volume":"36","author":"Nielsen","year":"2017","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/10550887.2015.1059225","article-title":"Methadone medical maintenance: an early 21st-century perspective","volume":"34","author":"Novick","year":"2015","journal-title":"J.\u00a0Addict. Dis."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/026988119801200103","article-title":"Conditioning factors in drug abuse: can they explain compulsion?","volume":"12","author":"O'Brien","year":"1998","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pnpbp.2013.08.012","article-title":"What is the role of the D3 receptor in addiction? A mini review of PET studies with [(11)C]-(+)-PHNO","volume":"52","author":"Payer","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib32","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.neuropharm.2008.12.007","article-title":"The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats","volume":"56","author":"Peng","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib33","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1038\/npp.2010.133","article-title":"Is slow-onset long-acting monoamine transport blockade to cocaine as methadone is to heroin? Implication for anti-addiction medications","volume":"35","author":"Peng","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/22560","article-title":"Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist","volume":"400","author":"Pilla","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","article-title":"Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START)","volume":"74","author":"Potter","year":"2013","journal-title":"J.\u00a0Stud. Alcohol Drugs"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib36","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0022-3565(24)39184-0","article-title":"Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A","volume":"294","author":"Reavill","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.drugalcdep.2007.02.012","article-title":"Prescription opioid abuse among enrollees into methadone maintenance treatment","volume":"90","author":"Rosenblum","year":"2007","journal-title":"Drug Alcohol Dependence"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/347146a0","article-title":"Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics","volume":"347","author":"Sokoloff","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/ejn.13390","article-title":"The dopamine D3 receptor, a quarter century later","volume":"45","author":"Sokoloff","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/ejn.13390","article-title":"The dopamine D3 receptor, a quarter century later","volume":"45","author":"Sokoloff","year":"2017","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib41","doi-asserted-by":"crossref","first-page":"17675","DOI":"10.1073\/pnas.1205297109","article-title":"Increased vulnerability to cocaine in mice lacking dopamine D3 receptors","volume":"109","author":"Song","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib42","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/npp.2015.223","article-title":"Dopamine D(2)-like receptors and behavioral economics of food reinforcement","volume":"41","author":"Soto","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0169-328X(02)00671-X","article-title":"Elevated D3 dopamine receptor mRNA in dopaminergic and dopaminoceptive regions of the rat brain in response to morphine","volume":"111","author":"Spangler","year":"2003","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib44","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1021\/jm000090i","article-title":"Design and synthesis oftrans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2- yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): a potent and selective dopamine D3Receptor antagonist with high oral bioavailability and CNS penetration in the rat","volume":"43","author":"Stemp","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00213-010-1942-4","article-title":"Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies","volume":"212","author":"Stoops","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/jpet.117.241141","article-title":"Effects of acute and chronic treatments with dopamine D2 and D3 receptor ligands on cocaine versus food choice in rats","volume":"362","author":"Thomsen","year":"2017","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib47","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/mp.2014.58","article-title":"Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers","volume":"19","author":"Volkow","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib48","doi-asserted-by":"crossref","first-page":"9595","DOI":"10.1523\/JNEUROSCI.22-21-09595.2002","article-title":"Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats","volume":"22","author":"Vorel","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/npp.2014.188","article-title":"Compulsive-like responding for opioid analgesics in rats with extended access","volume":"40","author":"Wade","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.007_bib50","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/acschemneuro.6b00297","article-title":"Dopamine D3\/D2 receptor antagonist PF-4363467 attenuates opioid drug-seeking behavior without concomitant D2 side effects","volume":"8","author":"Wager","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.007_bib51","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1527-3458.2007.00013.x","article-title":"Pharmacological actions of NGB 2904, a selective dopamine D3Receptor antagonist, in animal models of drug addiction","volume":"13","author":"Xi","year":"2007","journal-title":"CNS Drug Rev."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T16:28:40Z","timestamp":1750868920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817304240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":52,"alternative-id":["S0028390817304240"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.007","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel dopamine D3 receptor antagonists\/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}